Staphylococcus aureus produces the
superantigen toxic shock syndrome toxin 1 (TSST-1). When the bacterium invades the human circulation, this toxin can induce life-threatening gram-positive
sepsis. Current
sepsis treatment does not remove
bacterial toxins. Variable domains of llama heavy-chain
antibodies (VHH) against
toxic shock syndrome toxin 1 ([alpha]-TSST-1 VHH) were previously found to be effective in vitro. We hypothesized that removing
TSST-1 with [alpha]-TSST-1 VHH
hemofiltration filters would ameliorate experimental
sepsis in pigs. After assessing in vitro whether timely removing
TSST-1 interrupted TSST-1-induced mononuclear cell
TNF-[alpha] production, VHH-coated filters were applied in a porcine
sepsis model.
Clinical course, survival, plasma
interferon [gamma], and
TSST-1 levels were similar with and without VHH-coated filters as were
TSST-1 concentrations before and after the VHH filter. Plasma
TSST-1 levels were much lower than anticipated from the distribution of the amount of infused
TSST-1, suggesting compartmentalization to space or adhesion to surface not accessible to
hemofiltration or
pheresis techniques. Removing
TSST-1 from plasma was feasible in vitro. However, the [alpha]-TSST-1 VHH adsorption filter-based technique was ineffective in vivo, indicating that improvement of VHH-based
hemofiltration is required. Sequestration likely prevented the adequate removal of
TSST-1. The latter warrants further investigation of
TSST-1 distribution and clearance in vivo.